NK antibody therapy: KIR-ative intent

Nina Shah; Elizabeth J. Shpall

doi:10.1182/blood-2009-07-230904

NK antibody therapy: KIR-ative intent

Nina Shah, Elizabeth J. Shpall

Stem Cell Transplantation

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Abstract

In this issue of Blood, Romange and colleagues describe 1-7F9, a human monoclonal antibody targeting KIRs onNKcells.¹ This antibody activates NK cells by blocking the interaction between inhibitory KIRs and target cell HLA class I molecules. This effect is demonstrated by the authors in vitro and in a mouse model of AML.

Original language	English (US)
Pages (from-to)	2567-2568
Number of pages	2
Journal	Blood
Volume	114
Issue number	13
DOIs	https://doi.org/10.1182/blood-2009-07-230904
State	Published - 2009

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2009-07-230904

Cite this

@article{9f71a3f63e894bbba1795f6b9eb0b418,

title = "NK antibody therapy: KIR-ative intent",

abstract = "In this issue of Blood, Romange and colleagues describe 1-7F9, a human monoclonal antibody targeting KIRs onNKcells.1 This antibody activates NK cells by blocking the interaction between inhibitory KIRs and target cell HLA class I molecules. This effect is demonstrated by the authors in vitro and in a mouse model of AML.",

author = "Nina Shah and Shpall, {Elizabeth J.}",

year = "2009",

doi = "10.1182/blood-2009-07-230904",

language = "English (US)",

volume = "114",

pages = "2567--2568",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "13",

}

TY - JOUR

T1 - NK antibody therapy

T2 - KIR-ative intent

AU - Shah, Nina

AU - Shpall, Elizabeth J.

PY - 2009

Y1 - 2009

N2 - In this issue of Blood, Romange and colleagues describe 1-7F9, a human monoclonal antibody targeting KIRs onNKcells.1 This antibody activates NK cells by blocking the interaction between inhibitory KIRs and target cell HLA class I molecules. This effect is demonstrated by the authors in vitro and in a mouse model of AML.

AB - In this issue of Blood, Romange and colleagues describe 1-7F9, a human monoclonal antibody targeting KIRs onNKcells.1 This antibody activates NK cells by blocking the interaction between inhibitory KIRs and target cell HLA class I molecules. This effect is demonstrated by the authors in vitro and in a mouse model of AML.

UR - http://www.scopus.com/inward/record.url?scp=70449591587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449591587&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-07-230904

DO - 10.1182/blood-2009-07-230904

M3 - Comment/debate

C2 - 19779042

AN - SCOPUS:70449591587

SN - 0006-4971

VL - 114

SP - 2567

EP - 2568

JO - Blood

JF - Blood

IS - 13

ER -

NK antibody therapy: KIR-ative intent

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this